Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Dr. Reddy’s Laboratories announced on November 24, 2025, that it has received European Commission approval for AVT03, a biosimilar of Prolia® and Xgeva®, which are used to treat osteoporosis and prevent bone complications in cancer patients. This approval, based on comprehensive evidence and clinical trials, allows Dr. Reddy’s to market AVT03 across EU and EEA countries, enhancing its position in the biosimilars market and potentially increasing its market share in Europe and the US, where it holds exclusive commercialization rights.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company is committed to providing affordable and innovative medicines, offering a portfolio that includes APIs, generics, branded generics, biosimilars, and OTC products. Dr. Reddy’s focuses on therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology, with major markets in the USA, India, Russia, CIS countries, China, Brazil, and Europe.
Average Trading Volume: 1,009,787
Technical Sentiment Signal: Hold
Current Market Cap: $11.47B
Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.